Subscriber Authentication Point
lvrea
Home All issues Volume 26 / No 4 (Juillet 2017) Méd. Intensive Réa., 26 4 (2017) 296-310 References
Free Access
Issue
Méd. Intensive Réa.
Volume 26, Number 4, Juillet 2017
Médecine interne et transversalité
Page(s) 296 - 310
Section Mise au point / Update
DOI https://doi.org/10.1007/s13546-017-1287-7
Published online 10 July 2017
  • Ananth CV, Keyes KM, Wapner RJ, (2013) Pre-eclampsia rates in the United States, 1980-2010: age-period-cohort analysis. BMJ (Clinical research ed) 347: f6564 [Google Scholar]
  • Karumanchi SA, Maynard SE, Stillman IE, Epstein FH, Sukhatme VP, (2005) Preeclampsia: a renal perspective. Kidney Int 67: 2101–2113 [CrossRef] [PubMed] [Google Scholar]
  • Barton JR, Sibai BM, (2004) Diagnosis and management of hemolysis, elevated liver enzymes, and low platelets syndrome. Clin Perinatol 31: 807–833, vii [CrossRef] [PubMed] [Google Scholar]
  • Sibai BM, Ramadan MK, Usta I, Salama M, Mercer BM, Friedman SA, (1993) Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol 169: 1000–1006 [CrossRef] [PubMed] [Google Scholar]
  • Cavkaytar S, Ugurlu EN, Karaer A, Tapisiz OL, Danisman N, (2007) Are clinical symptoms more predictive than laboratory parameters for adverse maternal outcome in HELLP syndrome? Acta Obstet Gynecol Scand 86: 648–651 [CrossRef] [PubMed] [Google Scholar]
  • Sibai BM, (2004) Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol 103: 981–991 [CrossRef] [PubMed] [Google Scholar]
  • Abraham KA, Connolly G, Farrell J, Walshe JJ, (2001) The HELLP syndrome, a prospective study. Ren Fail 23: 705–713 [CrossRef] [PubMed] [Google Scholar]
  • Selçuk NY, Odabas AR, Cetinkaya R, Tonbul HZ, San A, (2000) Outcome of pregnancies with HELLP syndrome complicated by acute renal failure (1989-1999). Ren Fail 22: 319–327 [CrossRef] [PubMed] [Google Scholar]
  • Abraham KA, Kennelly M, Dorman AM, Walshe JJ, (2003) Pathogenesis of acute renal failure associated with the HELLP syndrome: a case report and review of the literature. Eur J Obstet Gynecol Reprod Biol 108: 99–102 [CrossRef] [PubMed] [Google Scholar]
  • Ibdah JA, Bennett MJ, Rinaldo P, Zhao Y, Gibson B, Sims HF, Strauss AW, (1999) A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women. N Engl J Med 340: 1723–1731 [CrossRef] [PubMed] [Google Scholar]
  • Knox TA, Olans LB, (1996) Liver disease in pregnancy. N Engl J Med 335: 569–576 [CrossRef] [PubMed] [Google Scholar]
  • Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaimé F, Dragon-Durey MA, Ngo S, Moulin B, Servais A, Provot F, Rostaing L, Burtey S, Niaudet P, Deschênes G, Lebranchu Y, Zuber J, Loirat C, (2013) Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 8: 554–562 [CrossRef] [PubMed] [Google Scholar]
  • Fakhouri F, Roumenina L, Provot F, Sallée M, Caillard S, Couzi L, Essig M, Ribes D, Dragon-Durey M-A, Bridoux F, Rondeau E, Frémeaux-Bacchi V, (2010) Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol 21: 859–867 [CrossRef] [Google Scholar]
  • Moatti-Cohen M, Garrec C, Wolf M, Boisseau P, Galicier L, Azoulay E, Stepanian A, Delmas Y, Rondeau E, Bezieau S, Coppo P, Veyradier A, Microangiopathies FRCfT, (2012) Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood 119: 5888–5897 [CrossRef] [Google Scholar]
  • Martin JN, Bailey AP, Rehberg JF, Owens MT, Keiser SD, May WL, (2008) Thrombotic thrombocytopenic purpura in 166 pregnancies: 1955-2006. Am J Obstet Gynecol 199: 98–104 [CrossRef] [PubMed] [Google Scholar]
  • Scully M, Thomas M, Underwood M, Watson H, Langley K, Camilleri RS, Clark A, Creagh D, Rayment R, Mcdonald V, Roy A, Evans G, McGuckin S, Ni Ainle F, Maclean R, Lester W, Nash M, Scott R, O Brien P, Registry cotUT, (2014) Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes. Blood 124: 211–219 [CrossRef] [Google Scholar]
  • Kremer Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN, (2010) Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 115: 1500–1511 [CrossRef] [Google Scholar]
  • Benhamou Y, Boelle P-Y, Baudin B, Ederhy S, Gras J, Galicier L, Azoulay E, Provôt F, Maury E, Pène F, Mira J-P, Wynckel A, Presne C, Poullin P, Halimi J-M, Delmas Y, Kanouni T, Seguin A, Mousson C, Servais A, Bordessoule D, Perez P, Hamidou M, Cohen A, Veyradier A, Coppo P, Microangiopathies RCfT, (2015) Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center. J Thromb Haemost 13: 293–302 [CrossRef] [PubMed] [Google Scholar]
  • Hanouna G, Morel N, Le Thi Huong D, Josselin L, Vauthier-Brouzes D, Saadoun D, Kettaneh A, Levesque K, Le Guern V, Goffinet F, Carbonne B, Amoura Z, Piette J-C, Nizard J, Costedoat-Chalumeau N, (2013) Catastrophic antiphospholipid syndrome and pregnancy: an experience of 13 cases. Rheumatology (Oxford) 52: 1635–1641 [CrossRef] [PubMed] [Google Scholar]
  • Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA, (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111: 649–658 [CrossRef] [PubMed] [Google Scholar]
  • Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennstrom M, Olovsson M, Brennecke SP, Stepan H, Allegranza D, Dilba P, Schoedl M, Hund M, Verlohren S, (2016) Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. N Engl J Med 374: 13–22 [CrossRef] [PubMed] [Google Scholar]
  • Venkatesha S, Toporsian M, Lam C, Hanai JI, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE, Roberts D, D’Amore PA, Epstein FH, Sellke FW, Romero R, Sukhatme VP, Letarte M, Karumanchi SA, (2006) Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12: 642–649 [CrossRef] [PubMed] [Google Scholar]
  • Hertig A, Fort J, Lefevre G, Chabbert-Buffet N, Uzan M, Rondeau E, Rozenberg P, (2010) Soluble endoglin in preeclamptic patients with or without HELLP syndrome. Am J Obstet Gynecol 202: 594.e591–594 [CrossRef] [Google Scholar]
  • Noris M, Galbusera M, Gastoldi S, Macor P, Banterla F, Bresin E, Tripodo C, Bettoni S, Donadelli R, Valoti E, Tedesco F, Amore A, Coppo R, Ruggenenti P, Gotti E, Remuzzi G, (2014) Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 124: 1715–1726 [CrossRef] [Google Scholar]
  • Fakhouri F, Jablonski M, Lepercq J, Blouin J, Benachi A, Hourmant M, Pirson Y, Dürrbach A, Grünfeld JP, Knebelmann B, Frémeaux-Bacchi V, (2008) Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome. Blood 112: 4542–4545 [CrossRef] [Google Scholar]
  • Crovetto F, Borsa N, Acaia B, Nishimura C, Frees K, Smith RJH, Peyvandi F, Palla R, Cugno M, Tedeschi S, Castorina P, Somigliana E, Ardissino G, Fedele L, (2012) The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome. J Matern Fetal Neonatal Med 25: 2322–2325 [CrossRef] [PubMed] [Google Scholar]
  • Coppo P, Veyradier A, Monge M, Thrombotiques RdEdM, (2006) [Acquired idiopathic thrombotic thrombocytopenic purpura: arguments for an autoimmune disease]. Presse Med 35: 1876–1886 [CrossRef] [PubMed] [Google Scholar]
  • Coppo P, Wolf M, Veyradier A, Bussel A, Malot S, Millot GA, Daubin C, Bordessoule D, Pène F, Mira JP, Heshmati F, Maury E, Guidet B, Boulanger E, Galicier L, Parquet N, Vernant JP, Rondeau E, Azoulay E, Schlemmer B, l’Adulte RdEdMTd, (2006) Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. Br J Haematol 132: 66–74 [CrossRef] [PubMed] [Google Scholar]
  • Moatti-Cohen M, Garrec C, Wolf M, Boisseau P, Galicier L, Azoulay E, Stepanian A, Delmas Y, Rondeau E, Bezieau S, Coppo P, Veyradier A; French Reference Center for Thrombotic Microangiopathies, (2012) Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood 119: 5888–5897 [CrossRef] [Google Scholar]
  • Veyradier A, Obert B, Houllier A, Meyer D, Girma JP, (2001) Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 98: 1765–1772 [CrossRef] [PubMed] [Google Scholar]
  • Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E, (2001) Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 98: 2730–2735 [CrossRef] [PubMed] [Google Scholar]
  • Loof AH, van Vliet HH, Kappers-Klunne MC, (2001) Low activity of von Willebrand factor-cleaving protease is not restricted to patients suffering from thrombotic thrombocytopenic purpura. Br J Haematol 112: 1087–1088 [CrossRef] [PubMed] [Google Scholar]
  • Lattuada A, Rossi E, Calzarossa C, Candolfi R, Mannucci PM, (2003) Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Haematologica 88: 1029–1034 [PubMed] [Google Scholar]
  • D’Angelo A, Fattorini A, Crippa L, (2009) Thrombotic microangiopathy in pregnancy. Thromb Res 123 Suppl 2: S56–62 [CrossRef] [Google Scholar]
  • Fakhouri F, Vercel C, Frémeaux-Bacchi V, (2012) Obstetric nephrology: AKI and thrombotic microangiopathies in pregnancy. Clin J Am Soc Nephrol 7: 2100–2106 [CrossRef] [PubMed] [Google Scholar]
  • George JN, Nester CM, McIntosh JJ, (2015) Syndromes of thrombotic microangiopathy associated with pregnancy. Hematology Am Soc Hematol Educ Program 2015: 644–648 [PubMed] [Google Scholar]
  • Chandran R, Serra-Serra V, Redman CW, (1992) Spontaneous resolution of pre-eclampsia-related thrombocytopenia. Br J Obstet Gynaecol 99: 887–890 [CrossRef] [PubMed] [Google Scholar]
  • Kremer Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN, (2010) Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 115: 1500–1511 [CrossRef] [Google Scholar]
  • Koehl B, Boyer O, Biebuyck-Gougé N, Kossorotoff M, Frémeaux-Bacchi V, Boddaert N, Niaudet P, (2010) Neurological involvement in a child with atypical hemolytic uremic syndrome. Pediatr Nephrol 25: 2539–2542 [CrossRef] [PubMed] [Google Scholar]
  • Frimat M, Decambron M, Lebas C, Moktefi A, Lemaitre L, Gnemmi V, Sautenet B, Glowacki F, Subtil D, Jourdain M, Rigouzzo A, Brocheriou I, Halimi J-M, Rondeau E, Noel C, Provôt F, Hertig A, (2016) Renal Cortical Necrosis in Postpartum Hemorrhage: A Case Series. Am J Kidney Dis 68: 50–57 [CrossRef] [PubMed] [Google Scholar]
  • Kaplan M, (2002) Eculizumab (Alexion). Curr Opin Investig Drugs 3: 1017–1023 [PubMed] [Google Scholar]
  • Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA, (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 325: 393–397 [CrossRef] [PubMed] [Google Scholar]
  • Nguyen L, Li X, Duvall D, Terrell DR, Vesely SK, George JN, (2008) Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006. Transfusion 48: 349–357 [CrossRef] [PubMed] [Google Scholar]
  • Scully M, Thomas M, Underwood M, Watson H, Langley K, Camilleri RS, Clark A, Creagh D, Rayment R, Mcdonald V, Roy A, Evans G, McGuckin S, Ni Ainle F, Maclean R, Lester W, Nash M, Scott R, O Brien P, Registry cotUT, (2014) Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes. Blood 124: 211–219 [CrossRef] [Google Scholar]
  • Thomas MR, Robinson S, Scully MA, (2016) How we manage thrombotic microangiopathies in pregnancy. Br J Haematol 173: 821–830 [CrossRef] [PubMed] [Google Scholar]
  • Balduini CL, Gugliotta L, Luppi M, Laurenti L, Klersy C, Pieresca C, Quintini G, Iuliano F, Re R, Spedini P, Vianelli N, Zaccaria A, Pogliani EM, Musso R, Bobbio Pallavicini E, Quarta G, Galieni P, Fragasso A, Casella G, Noris P, Ascari E, Group ITS, (2010) High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study. Ann Hematol 89: 591–596 [CrossRef] [PubMed] [Google Scholar]
  • Fakhouri F, Vernant J-P, Veyradier A, Wolf M, Kaplanski G, Binaut R, Rieger M, Scheiflinger F, Poullin P, Deroure B, Delarue R, Lesavre P, Vanhille P, Hermine O, Remuzzi G, Grünfeld J-P, (2005) Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 106: 1932–1937 [CrossRef] [Google Scholar]
  • Froissart A, Buffet M, Veyradier A, Poullin P, Provôt F, Malot S, Schwarzinger M, Galicier L, Vanhille P, Vernant JP, Bordessoule D, Guidet B, Azoulay E, Mariotte E, Rondeau E, Mira J-P, Wynckel A, Clabault K, Choukroun G, Presne C, Pourrat J, Hamidou M, Coppo P, Center FTMR, (2012) Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med 40: 104–111 [CrossRef] [PubMed] [Google Scholar]
  • Hull MJ, Eichbaum QG, (2006) Efficacy of rituximab and concurrent plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Clin Adv Hematol Oncol 4: 210–214 [PubMed] [Google Scholar]
  • Vazquez-Mellado A, Pequeño-Luévano M, Cantu-Rodriguez OG, Villarreal-Martínez L, Jaime-Pérez JC, Gomez-De-Leon A, De La Garza-Salazar F, Gonzalez-Llano O, Colunga-Pedraza P, Sotomayor-Duque G, Gomez-Almaguer D, (2016) More about low-dose rituximab and plasma exchange as front-line therapy for patients with thrombotic thrombocytopenic purpura. Hematology 21: 311–316 [CrossRef] [PubMed] [Google Scholar]
  • Page EE, Kremer Hovinga JA, Terrell DR, Vesely SK, George JN, (2016) Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura. Blood 127: 3092–3094 [CrossRef] [Google Scholar]
  • Hyrich KL, Verstappen SMM, (2014) Biologic therapies and pregnancy: the story so far. Rheumatology (Oxford) 53: 1377–1385 [CrossRef] [PubMed] [Google Scholar]
  • Cataland SR, Wu HM, (2015) Acquired thrombotic thrombocytopenic purpura: new therapeutic options and their optimal use. J Thromb Haemost 13 Suppl 1: S223–229 [CrossRef] [PubMed] [Google Scholar]
  • Jilma-Stohlawetz P, Gilbert JC, Gorczyca ME, Knöbl P, Jilma B, (2011) A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura. Thromb Haemost 106: 539–547 [CrossRef] [PubMed] [Google Scholar]
  • Cataland SR, Peyvandi F, Mannucci PM, Lämmle B, Kremer Hovinga JA, Machin SJ, Scully M, Rock G, Gilbert JC, Yang S, Wu H, Jilma B, Knoebl P, (2012) Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. Am J Hematol 87: 430–432 [CrossRef] [PubMed] [Google Scholar]
  • Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Knöbl P, Wu H, Artoni A, Westwood J-P, Mansouri Taleghani M, Jilma B, Callewaert F, Ulrichts H, Duby C, Tersago D, Investigators T, (2016) Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med 374: 511–522 [CrossRef] [PubMed] [Google Scholar]
  • Kremer Hovinga JA, Coppo P, Lämmle B, Moake JL, Miyata T, Vanhoorelbeke K, (2017) Thrombotic thrombocytopenic purpura. Nat Rev Dis Primers 3: 17020 [CrossRef] [PubMed] [Google Scholar]
  • Eskazan AE, (2016) Bortezomib therapy in patients with relapsed/refractory acquired thrombotic thrombocytopenic purpura. Ann Hematol 95: 1751–1756 [CrossRef] [PubMed] [Google Scholar]
  • Rottenstreich A, Hochberg-Klein S, Rund D, Kalish Y, (2016) The role of N-acetylcysteine in the treatment of thrombotic thrombocytopenic purpura. J Thromb Thrombolysis 41: 678–683 [CrossRef] [PubMed] [Google Scholar]
  • De Sousa Amorim E, Blasco M, Quintana L, Sole M, de Cordoba SR, Campistol JM, (2015) Eculizumab in pregnancy-associated atypical hemolytic uremic syndrome: insights for optimizing management. J Nephrol 28: 641–645 [CrossRef] [PubMed] [Google Scholar]
  • Ardissino G, Testa S, Possenti I, Tel F, Paglialonga F, Salardi S, Tedeschi S, Belingheri M, Cugno M, (2014) Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am J Kidney Dis 64: 633–637 [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.